Strategic partnerships Dignify Therapeutics operates in a niche neuro urology space with NIH funding and recent NIH grants, signaling openness to academic and government-backed collaboration. Target outreach to contract research organizations, academic medical centers, and biotechnology incubators that align with neurogenic bladder and bowel research to explore co development or sponsored studies.

Clinical development focus Lead assets DTI-117 and DTI-301 are at the forefront of restoring voluntary excretory function, presenting clear opportunities to engage late stage clinical trialists, consented patient cohorts, and neuro urology specialists for investigator initiated trials and strategic partnerships with pharma to accelerate development timelines.

Funding momentum With NIH grants and a visible funding runway, there is credibility to approach potential co development and licensing partners seeking to augment their neurology and urology portfolios, as well as investors looking for early stage biotech with grant-backed validation.

Industry visibility Participation in BIO conferences and investor forums indicates a readiness to engage investors and potential licensing partners; leverage these channels to arrange targeted meetings with biopharma players in bladder and bowel dysfunction, neurology, and specialty pharmaceuticals.

Leadership and governance Recent additions to the board and a specialized PI indicate an expanding governance and scientific advisory footprint, which can be marketed to potential strategic partners to signal strong leadership, credible trial oversight, and robust scientific guidance.